Regeneron's Q4 earnings report shows revenue growth, stable EYLEA sales, dividend announcement, and impressive growth for ...

The indication is based on a phase 3 trial – Empower-Lung 1 – that showed Libtayo given as a monotherapy cut the risk of death by 43% compared to chemotherapy in advanced, PD-L1-high patients ...

MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced positive updated data from its THIO-101 ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader ...

Libtayo plus chemotherapy increased median overall ... In the phase 3 KEYNOTE-716 trial, Keytruda improved recurrence-free survival when given to patients with high-risk advanced melanoma.

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

In addition, the company’s cancer medicine Libtayo brought in $289 million in ... business continues performing well, and given the outlook from here, we took advantage of what we consider ...

It is administered through intravenous route as infusion. The therapeutic candidate is developed based on Regeneron's VelocImmune technology and Veloci-Bi platform. The therapeutic candidate is used ...